KCKwun Chuen Gary Chan

Kwun Chuen Gary Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kwun Chuen Gary Chan has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Instrumental Support Calls vs. Caring Contacts Texts to Prevent Suicide in Adolescents and Adults: The SPARC Randomized Clinical Trial

    by Anna K. Radin, Jenny Shaw, Siobhan P. Brown, Hilary Flint, Tara Fouts, Elizabeth McCue, Anton Skeie, Cecelia Peña, Jonathan Youell, Matthew Biss, et al.

    PsychiatryOnline.org is the platform for all American Psychiatric Association Publishing journals, DSM, and bestselling textbooks, as well as APA Practice Guidelines, and continuing medical education.

  • Open Access

    Association of maternal height with pregnancy complications: Analyses of two cohorts

    by Ruchi Tiwari, Pandora L. Wander, Kwun C. G. Chan, Eeeseung Byun, Daniel A. Enquobahrie

    Background: Height is inversely associated with risk of cardiovascular and metabolic conditions in nonpregnant populations. Whether maternal height is independently associated with pregnancy complications, after accounting for prepregnancy weight, remains less clear. Objective: To investigate associations of maternal height with pregnancy complications, independent of prepregnancy weight, and to examine the role of infant sex and race/ethnicity in these associations. Methods: We conducted a secondary analysis of data from the Omega and Hyperglycemia and Adverse Pregnancy Outcome (HAPO) prospective cohort studies of pregnant women (total N = 8763). Cohort‐specific short (<20th percentile), average (20th–80th percentile), and tall (≥80th percentile) height categories were defined. Gestational diabetes mellitus (GDM), preterm birth (PTB; Omega only), and preeclampsia were considered outcomes. We fit cohort‐specific unadjusted and adjusted modified Poisson regression models with robust standard errors and estimated relative risks (RRs) and 95% confidence intervals (CIs) associated with each 5‐cm greater maternal height. We fit similar models to examine risks among women with short or tall height compared with average height. We evaluated race/ethnicity and infant sex as potential modifiers of height–GDM associations using interaction models. Results: Each 5‐cm greater maternal height was associated with lower GDM risk in both cohorts, with a modest association in Omega and a larger association in HAPO (Omega: adjusted RR [aRR], 0.99; 95% CI, 0.98, 0.99; HAPO: aRR, 0.84; 95% CI, 0.78, 0.90). Short women had higher GDM risk (Omega: aRR, 1.05; 95% CI, 1.03, 1.07; HAPO: aRR, 1.44; 95% CI, 1.18, 1.75), and tall women had lower GDM risk (Omega: aRR, 0.98; 95% CI, 0.96, 0.99; HAPO: aRR, 0.71; 95% CI, 0.56, 0.89), compared with women with average height. In Omega, linear height was associated with slightly lower preeclampsia risk (aRR, 0.99; 95% CI, 0.99, 0.99) and slightly greater PTB risk (aRR, 1.01; 95% CI, 1.00, 1.01). Infant sex or race/ethnicity did not meaningfully modify the association between height and GDM in either cohort. Conclusion: Maternal height was inversely associated with GDM risk in both cohorts. We also observed small, cohort‐specific associations of height with PTB and preeclampsia in Omega. These findings suggest that maternal height may provide modest information beyond conventional maternal body‐size measures, although its clinical utility for individual risk prediction or targeted monitoring may be limited and requires further evaluation.

  • Open Access

    Estimating controlled direct treatment effects on pain intensity using structural mean models

    by Rui Wang, Patrick J. Heagerty, Kwun Chuen Gary Chan, Pradeep Suri

    Introduction: Without valid inclusion of concurrent analgesic use, the primary analyses of pain intensity in pain randomized controlled trials (RCTs) may produce diminished estimated treatment effects. Methods: We used contemporary causal inference methods to reanalyze RCT data examining the effect of epidural steroid injection (ESI) as an example of a pain treatment. Specifically, we define an “attributable to ESI estimand,” which is the controlled direct effect of ESI. We used a simple composite pain intensity outcome, the QPAC 1.5, and structural mean models (SMM) to estimate the target estimand. Compared with traditional methods such as strict intention to treat analysis (strict ITT), SMMs can account for analgesic use without assuming no unmeasured confounding between the analgesic use and the outcome. We estimated treatment effects of ESI on leg pain intensity using the numeric rating scale with strict ITT, 3 SMM estimating methods (estimating equations, g-estimation, and generalized method of moments), and the QPAC 1.5 . Results: The treatment effect of ESI on leg pain intensity using strict ITT was −0.751 numeric rating scale points (95% confidence interval [CI]: −1.287 to −0.214). Estimates for the attributable to ESI estimand were −0.864 (95% CI: −3.207 to 1.478) for estimating equations, −0.935 (95% CI: −1.779 to 0.090) for g-estimation, −0.653 (95% CI: −1.218 to −0.089) for generalized method of moments, and −0.930 (95% CI: −1.508 to −0.352) for the QPAC1.5. Discussion: We illustrate how contemporary causal inference methods and alternative estimands can be used to account for concurrent analgesic use in pain RCTs in a manner that may result in larger treatment effects.

  • Open Access

    Comparable performance of the NACC Uniform Data Set version 3 neuropsychological test battery in assessing longitudinal cognitive change for African American and White participants

    by Kwun C. G. Chan, Hiroko H. Dodge, Mary Sano, Rhoda Au, Suzanne Craft, Allan I. Levey, Sandra Weintraub, Walter A. Kukull, Andrew J. Saykin, Lisa L. Barnes

    INTRODUCTION: Alzheimer's Disease Research Centers have used the Uniform Data Set Version 3 (UDS3) neuropsychological battery since 2015, but whether it exhibits differential sensitivity to change across race is unknown. We examined whether the UDS3 cognitive battery was comparably sensitive to longitudinal change between African American and White participants. METHODS: Data were obtained from the National Alzheimer's Coordinating Center (NACC). Linear mixed‐effects models examined racial differences in baseline and longitudinal change in standardized test scores, controlling for age, sex, education, recruitment source, health factors, family history of dementia, and diagnostic groups defined by baseline and longitudinal changes in Clinical Dementia Rating (CDR) scores. RESULTS: Compared to White participants, African American participants had significantly lower baseline Z ‐scores on all tests (difference: −0.097 to −0.592). Nevertheless, differences in longitudinal decline were non‐significant (annualized difference: −0.018 to 0.031). DISCUSSION: Despite baseline score differences, longitudinal change relative to clinical ratings appears comparable across racial groups. Highlights: Version 3 of the NACC Uniform Data Set neuropsychological battery (UDS3) has been implemented since 2015 and administered to over 14,000 participants. We observed small differences in longitudinal decline across all test scores when comparing White and African American participants. The findings support the continued use of the UDS3 battery in ADRCs and its potential applicability in other studies of cognitive aging and decline.

  • Open Access

    NACC data: Who is represented over time and across centers, and implications for generalizability

    by Kwun C. G. Chan, Fan Xia, Walter A. Kukull

    INTRODUCTION: Since 2005, the Alzheimer's Disease Research Centers (ADRCs) have recruited participants into the Uniform Data Set (UDS), but enrollment trends and center‐level differences remain underexplored. This study investigates temporal patterns and heterogeneity in recruitment across ADRCs, with implications for generalizability. METHODS: Using data from the National Alzheimer's Coordinating Center (NACC), we assessed trends and between‐center variation in baseline characteristics, including age, sex, race, education, clinical diagnosis, referral source, family history, and co‐participant relationship. RESULTS: All characteristics except sex and family history showed directional shifts over time. Substantial between‐center heterogeneity was observed in all variables examined. DISCUSSION: Temporal changes and site‐level variability in participant profiles highlight challenges and opportunities for generalizing findings from UDS data. Although not nationally representative, statements about generalization could often be made using UDS data, with strengthened inferences and enhanced transparency through analytic approaches such as sensitivity analysis or meta‐analytic techniques treating centers as separate studies. Highlights: The National Alzheimer's Coordinating Center (NACC) Uniform Data Set has enrolled participants for 20 years across more than 40 centers. We identified temporal trends and site‐level variation in participant characteristics in the initial visit. Despite being a volunteer sample, modern epidemiologic and biostatistical approaches can help assess and enhance the generalizability of scientific findings derived from NACC data.


  • Weighted Brier Score—An Overall Summary Measure for Risk Prediction Models with Clinical Utility Consideration

    by Kehao Zhu, Yingye Zheng, Kwun Chuen Gary Chan

    As advancements in novel biomarker-based algorithms and models accelerate their use in disease risk prediction, it is crucial to evaluate these models within the context of their intended clinical application. Prediction models output the absolute risk of disease; subsequently, patient counseling and shared decision-making are based on the estimated individual risk and cost-benefit assessment. The overall impact of the application is referred to as clinical utility, which received significant attention and desire to incorporate into model assessment lately. The classic Brier score is a popular measure of prediction accuracy; however, it is insufficient for effectively assessing clinical utility. To address this limitation, we propose a class of weighted Brier scores that aligns with the decision-theoretic framework of clinical utility. Additionally, we decompose the weighted Brier score into discrimination and calibration components, and we link the weighted Brier score to the H measure, which has been proposed as an alternative to the area under the receiver operating characteristic curve. This theoretical link to the H measure further supports our weighting method and underscores the essential elements of discrimination and calibration in risk prediction evaluation. The practical use of the weighted Brier score as an overall summary is demonstrated using data from a prostate cancer study.


  • Semiparametric joint modeling for biomarker trajectory before disease onset

    by Yifei Sun, Xiwen Zhao, Kwun Chuen Gary Chan, Wanwan Xu, Heather Allore, Yize Zhao

    Understanding how biomarkers change in relation to disease pathogenesis is a key area in biomedical research. We propose a semiparametric joint model to analyze the temporal evolution of biomarkers prior to the onset of disease. The model allows for a flexible biomarker trajectory that depends on two time scales: a natural time scale such as age and time to disease onset. In practice, the natural time scale often differs from time-on-study, leading to analytical challenges such as left-truncation bias. We introduce a profile kernel estimating equation approach to estimate regression coefficients and unspecified baseline mean trajectory functions. We establish the large-sample properties of the proposed estimators and conduct simulation studies to evaluate their finite-sample performance. Our method is applied to investigate brain biomarker trajectories before the onset of preclinical Alzheimer’s disease. We observed a decline in cortical thickness prior to disease onset across brain regions, with APOE4 carriers showing lower levels compared to non-carriers.

  • Open Access

    Adaptive Reduction of Curse of Dimensionality in Nonparametric Instrumental Variable Estimation

    by Ming-Yueh Huang, Kwun Chuen Gary Chan

    Nonparametric estimation of instrumental variable treatment effects typically builds on various nonparametric identification results. However, these estimators often face challenges from the curse of dimensionality in practice, as multi-dimensional covariates are common. To address this issue, we investigate the nonparametric identification of a range of treatment effects within different sufficient dimension reduction models. We also examine the efficiency of estimation and find that, unlike fully nonparametric approaches, nonparametric estimators derived from maximal dimension reduction based on identification results may not be efficient. We study the conditions for achieving maximal dimension reduction to ensure efficiency for a binary instrumental variable and extend these results to multivariate and general instrumental variables. The proposed nonparametric sufficient dimension reduction framework imposes no constraints on the distribution of the observed data while mitigating the curse of dimensionality in a data-adaptive manner.


  • Open Access

    Association of binge alcohol use with functional outcomes among individuals with COVID-19 infection

    by Sebastian T Tong, Michael Gottlieb, Imtiaz Ebna Mannan, Zihan Zheng, Manisha Sinha, Michelle Santangelo, Kristyn Gatling, Efrat Kean, Phillip Watts, Ralph Wang, et al.

    Aims: Alcohol consumption along with negative sequelae from excess alcohol intake increased during the COVID-19 pandemic. We evaluated the association between binge alcohol use and long-term functional outcomes among COVID-19-positive individuals. Methods: Using a prospective, longitudinal, multisite cohort study design, we evaluated the association between binge alcohol use and mental and physical functional outcomes using Patient-Reported Outcomes Measurement Information System (PROMIS)-29 scores three and six months postinfection. Eligible patients were those who presented with COVID-19-like symptoms, tested positive for COVID-19, and completed a three-month survey. Binge drinking was identified at the time of infection using the Tobacco, Alcohol, Prescription medication and other Substance use screener. Generalized estimating equation models, adjusted for demographic characteristics, social determinants of health, substance use, comorbidities, and COVID-19 vaccine status, were used to assess the association between binge alcohol use and mental and physical functional outcomes. Results: Of 3529 individuals, 23.7% screened positive for binge drinking. At three months, prior self-reported binge drinking was associated with differences in physical function [estimate: 1.08; 95% confidence interval (CI) 0.44, 1.71], pain interference (estimate: −0.86; 95% CI −1.57, −0.15), and physical health (estimate: 1.09; 95% CI 0.43, 1.75). At six months, no associations were found between binge drinking and outcomes. Conclusions: Binge alcohol use before COVID-19 infection was associated with statistically significant but clinically irrelevant improvements in function at three months, which were not sustained at six months. Postinfectious and postpandemic stressors may have played a larger impact on functional outcomes than binge alcohol use. A higher frequency of binge drinking and its association with functional outcomes, particularly among individuals with COVID-19 warrants further study.